Changing blood markers alter REM sleep patterns in narcolepsy

Targeting metabolic markers could improve sleep for NT1 patients

Written by Steve Bryson PhD |

Two labeled vials lie on a counter in a laboratory alongside a rack of vials filled with blood.

Researchers tied two blood markers to REM sleep patterns in type 1 narcolepsy.

Changes in two metabolic markers altered rapid eye movement (REM) sleep, the sleep stage with high brain activity and vivid dreaming, among people with narcolepsy type 1 (NT1), a study found.

Elevated blood levels of uric acid were tied to a lower REM frequency and a severe impairment of REM duration. Meanwhile, a low atherogenic index of plasma, a fat-based marker linked to higher cardiovascular disease risk, reflected mild to moderate REM duration problems.

The researchers recommended that treatment for mild to moderate REM maintenance impairment focus on weight reduction and modulation of blood fats. In contrast, REM initiation and severe REM maintenance impairments should prioritize lowering uric acid.

“Staged, targeted metabolic interventions may improve REM impairment in NT1,” the team wrote in the study, “Correlation analysis between metabolic indices and REM sleep architecture in patients with type 1 narcolepsy,” published in Sleep and Biological Rhythms.

NT1 is caused by the loss of brain cells that produce hypocretin (also known as orexin), a chemical that controls wakefulness and sleep.

Recommended Reading
An image shows a person sleeping on a tree branch with clouds and a blue sky in the background.

Daytime sleep patterns may aid narcolepsy diagnosis, study finds

Metabolism, sleep, and narcolepsy

NT1 symptoms include excessive daytime sleepiness and cataplexy (sudden loss of muscle tone), as well as impaired REM sleep, seen as frequent REM onset and difficulty maintaining REM sleep. People with NT1 can also live with obesity, abnormal blood fats (lipids), and hyperuricemia, meaning abnormally high blood levels of uric acid, a metabolic byproduct.

However, it remains unclear whether metabolic markers such as obesity, uric acid, and blood fats influence REM sleep impairment in NT1.

To find out, scientists in China enrolled 50 adults (65.2% men) with untreated NT1 and 50 age- and sex-matched healthy controls. All patients underwent an overnight sleep study and a multiple sleep latency test to measure how quickly they fell asleep and entered REM sleep.

Compared with controls, NT1 patients had significantly higher body mass index (BMI), a measure of body fat content based on height and weight. Blood tests also showed elevated mean levels of total cholesterol, triglycerides, the body’s most common fat, and alanine aminotransferase (a liver-damage marker).

The mean level of HDL cholesterol, often called good cholesterol, was significantly lower in patients than controls, while LDL cholesterol, known as bad cholesterol, was marginally higher. Patients also had an increased risk of cardiovascular disease, as indicated by a lower AIP, the level of fasting triglycerides relative to HDL cholesterol.

In a statistical analysis, uric acid levels, AIP, and BMI were each independently associated with NT1 after accounting for age, sex, and AIP.

The team then compared metabolic markers to REM frequency and duration. Here, elevated uric acid levels correlated with less frequent REM sleep onset, even after accounting for BMI. After adjusting for AIP, a link between higher BMI and lower REM frequency was also significant.

In contrast, after adjusting for BMI, uric acid and AIP were not linked to REM duration.

The researchers built models to predict different levels of REM impairment based on the metabolic factors. Uric acid was a reliable predictor for tracking specific REM sleep frequency thresholds. For example, for an REM frequency lower than 3, the specificity was 85.7%, meaning it accurately rules out cases where REM frequency is not lower than 3.

In comparison, the AIP emerged as the primary predictor for mild-to-moderate REM duration impairment, with a specificity of 95.2%. For severe impairment, however, AIP lost predictive value, and uric acid became the sole predictor, with a specificity of 83.3%.

These findings suggest that “severe REM maintenance impairment decouples from lipid metabolism dependence and becomes associated with [uric acid]-related pathways,” the team wrote.

“Clinical interventions should adopt a staging strategy,” the researchers wrote. “Early mild-to-moderate maintenance impairment should focus on weight reduction and lipid modulation, while REM initiation deficits and severe maintenance impairment should prioritize urate-lowering as the core therapeutic target.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.